KRAS and neoplasm: Finally, a recent study by Zulato et al. [22] demonstrated in a larger cohort of 58 patients with advanced disease carrying KRAS mutations in tumor tissue that increasing KRAS MAF in plasma during treatment was associated with increased probability of PD and conferred a negative impact on both PFS and OS.